A Phase 1 interventional study of Lasmiditan and Alprazolam in Recreational Drug Use and Prescription Drug Abuse (Not Dependent), sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-10.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,589 studies in Substance-Related Disorders with a site in United States — 249 open to participants now, 313 under way, 4 of them phase 3. Substance-Related Disorders · United States.
Among the 1,589 studies in Substance-Related Disorders with a site in United States, this one is the 772nd largest by enrollment of the 1,447 interventional ones that give a count, is one of 74 that started in 2017, is one of 131 in phase 1, and was the 886th registered.
2,241 studies on the registry are indexed under Substance-Related Disorders; 409 are open to participants now.
Browse Substance-Related Disorders studies →249 of the 1,589 studies in Substance-Related Disorders with a site in United States are open now. Recruiting first, the newest first:
Emory University · Sites in United States
Ages 18+ · Healthy volunteers
National Institute on Drug Abuse (NIDA) · Sites in United States
Ages 18–120
National Institute on Drug Abuse (NIDA) · Sites in United States
Ages 18–65 · Healthy volunteers
University of Massachusetts, Worcester · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 264 Substance-Related Disorders studies recruiting now, 129 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 89 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,589 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 172 · Phase 2 242 · Phase 3 79 · Phase 4 67
First in 1990; this study’s year is marked. 74 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 96 is below the median of 108 across 1,843 interventional studies indexed under Substance-Related Disorders.
Median enrollment 104 across the 1,447 interventional studies, 234 across the 137 observational. Of the 1,174 that completed or were terminated, 376 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
83 of 1,589 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 2 studies filed under Substance-Related Disorders — fewer than ten, so there is no comparison to draw.
99 of the studies in Substance-Related Disorders with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07566273Cornell UniversityMicropractices for Unhoused LGBTQ Youth | 2026-11 |
| NCT05897164Evidence-Based Practice Institute, Seattle, WAMobile Technology to Reduce Teen Substance Misuse | 2026-11-30 |
| NCT04317482University of ArkansasThe Human Stress Response in a Simulated ED Setting | 2026-12 |
| NCT05713695University of Massachusetts, WorcesterSupporting Treatment Access and Recovery Through Linkage and Support | 2026-12 |
| NCT03539575Yale UniversityCB1R in Synthetic Psychoactive Cannabinoids | 2026-12 |
Add all 99 to your calendar (.ics) → With an account.
Among the 1,589 studies in Substance-Related Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the abuse potential of study drug lasmiditan.
Lasmiditan will be compared to a marketed benzodiazepine, alprazolam (positive control), as well as to placebo (dummy substance that looks like lasmiditan or alprazolam without any active drug) to determine the potential for drug abuse. The dosages will be in tablet form and will be taken orally (by mouth).
This study will last about 55 days, including screening. Screening will occur within 28 days prior to qualification phase.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo was administered orally in one of five treatment periods
Drug: Placebo
2 mg of alprazolam was administered orally in one of five treatment periods
Drug: Alprazolam
100 mg of lasmiditan was administered orally in one of five treatment periods
Drug: Lasmiditan
200 mg of lasmiditan was administered orally in one of five treatment periods
Drug: Lasmiditan
400 mg of lasmiditan was administered orally in one of five treatment periods
Drug: Lasmiditan
Administered orally
Also known as: LY573144
Administered orally
Administered orally
Pharmacodynamics (PD): Maximal Effect Score (Emax) of Bipolar Drug Liking Visual Analog Scale (VAS) Scores
The Emax of Bipolar Drug Liking VAS Scores were derived as the maximum at-the-moment Drug Liking VAS score where the time to Emax was the corresponding time point at which the maximum score occurred. The bipolar Drug Liking VAS is consistent with FDA Guidance (January 2017) such that placebo should produce a score between 40 and 60 representing neutral drug-liking (ie, neither like nor dislike); a score ranging from 0 to 100 and a score of 0 indicates strong disliking, and a score of 100 indicates strong liking. Least squares mean (LS mean) was calculated using a linear mixed-effects model, including period, sequence, and treatment as fixed effects, and subject as a random effect, was used to evaluate the hypothesis tests of primary interest (at-the-moment Drug Liking) at the Emax.
Time frame: Each Phase: 24 Hours
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Lasmiditan
Pharmacokinetics (PK) defined as the maximum observed drug concentration (Cmax) of lasmiditan
Time frame: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours Post Dose
PK: Area Under the Curve of Lasmiditan From Zero to Infinity (AUC[0-∞])
PK defined as the area under the curve of lasmiditan from zero to infinity (AUC\[0-∞\])
Time frame: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours Post Dose
PD: Maximal Drug Effects (Emax) Visual Analog Scale (VAS)
Drug Effects VAS Battery lists a series of measures that evaluate different effects of the abuse potential of the study drug. Scales include: Overall drug liking (overall, my liking for this drug is) and ranges from 0 definitely not to 100 definitely so. Take Drug Again (I would take this drug again) and ranges from 0 definitely not to 100 definitely so. Good effects (I can feel good drug effects) and ranges from 0 definitely not to 100 definitely so. Bad effects (I can feel bad drug effects) and ranges from 0 definitely not to 100 definitely so. High (I am feeling) and ranges from 0 not at all high to 100 extremely high. Emax is derived as the maximum score across all postdose time points for each participant. Least Square (LS) Mean is calculated using the linear mixed-effects model with period, sequence and treatment as fixed effects and participant as a random effect.
Time frame: Each Phase: Predose, 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 4.5, 5, 6, 8, 12, 24 Hours Post Dose
PD: Maximal Drug Effects (Emax) VAS (Hallucinations)
Drug Effects VAS Battery lists a series of measures that evaluate different effects of the abuse potential of the study drug. The hallucinations scale is presented meaning (I am hallucinating) and ranges from 0 not at all to 100 extremely. Emax is derived as the maximum score across all postdose time points for each participant. Median and interquartile range are reported for each treatment group.
Time frame: Each Phase: Predose, 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 4.5, 5, 6, 8, 12, 24 Hours Post Dose
PD: Minimum Drug Effects (Emin) Visual Analog Scale (VAS)
Drug Effects VAS Battery lists a series of measures that evaluate different effects of the abuse potential of the study drug. The scales included: Alertness/Drowsiness (I am feeling) ranges from 0 very drowsy to 100 very alert. Agitation/Relaxation (my mood is) and ranges from 0 very relaxed to 100 very agitated. Emin is derived across all postdose time points for each participant. LS Mean was calculated using the linear mixed-effects model with period, sequence and treatment as fixed effects and participant as a random effect.
Time frame: Each Phase:Predose, 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 4.5, 5, 6, 8, 12, 24 Hours Post Dose
PD: Mean Scores on Drug Similarity VAS Measures
Participants marked a point on a 100-mm horizontal line that best represented their response to the given question. The endpoints of each electronic scale were marked with descriptive anchors on a scale from 0 to 100 (Fraser et al. 1961; Bond and Lader 1974; Bigelow 1991; Shram et al. 2010). In the "How similar" questions, ranges from 0 to 100 and a score of 0 indicates definitely not similar, and a score of 100 indicates definitely similar.
Time frame: Each Phase: 24 Hours Post Dose
| Milestone | Qualification Phase - Alprazolam Then Placebo Sequence 1 | Qualification Phase - Placebo Then Alprazolam (Alp) Sequence 2 | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Sequence 5 | Sequence 6 | Sequence 7 | Sequence 8 | Sequence 9 | Sequence 10 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 48 | 48 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Received at least one dose of study drug | 47 | 47 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 47 | 47 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Qualification Phase - Alprazolam Then Placebo Sequence 1 | Qualification Phase - Placebo Then Alprazolam (Alp) Sequence 2 | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Sequence 5 | Sequence 6 | Sequence 7 | Sequence 8 | Sequence 9 | Sequence 10 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 47 | 47 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 30 | 28 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 17 | 19 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Failure to meet randomization criteria | 14 | 15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Qualification Phase - Alprazolam Then Placebo Sequence 1 | Qualification Phase - Placebo Then Alprazolam (Alp) Sequence 2 | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Sequence 5 | Sequence 6 | Sequence 7 | Sequence 8 | Sequence 9 | Sequence 10 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 6 | 6 | 5 | 6 | 6 | 6 | 6 | 6 | 5 | 6 |
| Received at least one dose of study drug | 0 | 0 | 6 | 6 | 5 | 6 | 6 | 6 | 6 | 6 | 5 | 6 |
| Completed | 0 | 0 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 5 | 5 |
| Not completed | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Milestone | Qualification Phase - Alprazolam Then Placebo Sequence 1 | Qualification Phase - Placebo Then Alprazolam (Alp) Sequence 2 | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Sequence 5 | Sequence 6 | Sequence 7 | Sequence 8 | Sequence 9 | Sequence 10 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 5 | 5 |
| Completed | 0 | 0 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 5 | 5 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Qualification Phase - Alprazolam Then Placebo Sequence 1 | Qualification Phase - Placebo Then Alprazolam (Alp) Sequence 2 | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Sequence 5 | Sequence 6 | Sequence 7 | Sequence 8 | Sequence 9 | Sequence 10 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 5 | 5 |
| Completed | 0 | 0 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 5 | 5 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Qualification Phase - Alprazolam Then Placebo Sequence 1 | Qualification Phase - Placebo Then Alprazolam (Alp) Sequence 2 | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Sequence 5 | Sequence 6 | Sequence 7 | Sequence 8 | Sequence 9 | Sequence 10 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 5 | 5 |
| Completed | 0 | 0 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 5 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Milestone | Qualification Phase - Alprazolam Then Placebo Sequence 1 | Qualification Phase - Placebo Then Alprazolam (Alp) Sequence 2 | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Sequence 5 | Sequence 6 | Sequence 7 | Sequence 8 | Sequence 9 | Sequence 10 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 5 | 4 |
| Completed | 0 | 0 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 5 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The Emax of Bipolar Drug Liking VAS Scores were derived as the maximum at-the-moment Drug Liking VAS score where the time to Emax was the corresponding time point at which the maximum score occurred. The bipolar Drug Liking VAS is consistent with FDA Guidance (January 2017) such that placebo should produce a score between 40 and 60 representing neutral drug-liking (ie, neither like nor dislike); a score ranging from 0 to 100 and a score of 0 indicates strong disliking, and a score of 100 indicates strong liking. Least squares mean (LS mean) was calculated using a linear mixed-effects model, including period, sequence, and treatment as fixed effects, and subject as a random effect, was used to evaluate the hypothesis tests of primary interest (at-the-moment Drug Liking) at the Emax.
| millimeter (mm) | Placebo | Alprazolam - 2 mg | Lasmiditan - 100 mg | Lasmiditan - 200 mg | Lasmiditan - 400 mg |
|---|---|---|---|---|---|
| Pharmacodynamics (PD): Maximal Effect Score (Emax) of Bipolar Drug Liking Visual Analog Scale (VAS) Scores | 53.0 ± 1.94 | 85.4 ± 1.94 | 68.6 ± 1.94 | 73.3 ± 1.94 | 76.6 ± 1.94 |
Pharmacokinetics (PK) defined as the maximum observed drug concentration (Cmax) of lasmiditan
| nanogram/milliliter (ng/mL) | Lasmiditan - 100 mg | Lasmiditan - 200 mg | Lasmiditan - 400 mg |
|---|---|---|---|
| Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Lasmiditan | 132 ± 37 | 299 ± 35 | 689 ± 34 |
PK defined as the area under the curve of lasmiditan from zero to infinity (AUC\[0-∞\])
| nanogram*hour/milliliter (ng*h/mL) | Lasmiditan - 100 mg | Lasmiditan - 200 mg | Lasmiditan - 400 mg Dose |
|---|---|---|---|
| PK: Area Under the Curve of Lasmiditan From Zero to Infinity (AUC[0-∞]) | 856 ± 32 | 1810 ± 35 | 3920 ± 28 |
Drug Effects VAS Battery lists a series of measures that evaluate different effects of the abuse potential of the study drug. Scales include: Overall drug liking (overall, my liking for this drug is) and ranges from 0 definitely not to 100 definitely so. Take Drug Again (I would take this drug again) and ranges from 0 definitely not to 100 definitely so. Good effects (I can feel good drug effects) and ranges from 0 definitely not to 100 definitely so. Bad effects (I can feel bad drug effects) and ranges from 0 definitely not to 100 definitely so. High (I am feeling) and ranges from 0 not at all high to 100 extremely high. Emax is derived as the maximum score across all postdose time points for each participant. Least Square (LS) Mean is calculated using the linear mixed-effects model with period, sequence and treatment as fixed effects and participant as a random effect.
| mm | Placebo | Alprazolam - 2 mg | Lasmiditan - 100 mg | Lasmiditan - 200 mg | Lasmiditan - 400 mg |
|---|---|---|---|---|---|
| Overall Drug Liking | 53.1 ± 2.41 | 86.2 ± 2.41 | 71.7 ± 2.41 | 72.2 ± 2.41 | 77.4 ± 2.41 |
| Take Drug Again | 52.0 ± 2.70 | 86.0 ± 2.70 | 71.1 ± 2.70 | 72.7 ± 2.70 | 77.3 ± 2.70 |
| Good Effects | 10.8 ± 4.10 | 80.5 ± 4.10 | 46.4 ± 4.10 | 62.9 ± 4.10 | 63.8 ± 4.10 |
| Bad Effects | 2.47 ± 3.22 | 22.9 ± 3.22 | 7.51 ± 3.22 | 9.75 ± 3.22 | 15.0 ± 3.22 |
| Any Effects | 8.35 ± 4.05 | 83.7 ± 4.05 | 53.3 ± 4.05 | 65.1 ± 4.05 | 73.2 ± 4.04 |
| High | 8.61 ± 3.89 | 77.2 ± 3.89 | 43.0 ± 3.89 | 56.1 ± 3.89 | 67.0 ± 3.89 |
Drug Effects VAS Battery lists a series of measures that evaluate different effects of the abuse potential of the study drug. The hallucinations scale is presented meaning (I am hallucinating) and ranges from 0 not at all to 100 extremely. Emax is derived as the maximum score across all postdose time points for each participant. Median and interquartile range are reported for each treatment group.
| mm | Placebo | Alprazolam - 2 mg | Lasmiditan - 100 mg | Lasmiditan - 200 mg | Lasmiditan - 400 mg |
|---|---|---|---|---|---|
| PD: Maximal Drug Effects (Emax) VAS (Hallucinations) | 0 (0 to 0) | 0 (0 to 1.00) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) |
Drug Effects VAS Battery lists a series of measures that evaluate different effects of the abuse potential of the study drug. The scales included: Alertness/Drowsiness (I am feeling) ranges from 0 very drowsy to 100 very alert. Agitation/Relaxation (my mood is) and ranges from 0 very relaxed to 100 very agitated. Emin is derived across all postdose time points for each participant. LS Mean was calculated using the linear mixed-effects model with period, sequence and treatment as fixed effects and participant as a random effect.
| mm | Placebo | Alprazolam - 2 mg | Lasmiditan - 100 mg | Lasmiditan - 200 mg | Lasmiditan - 400 mg |
|---|---|---|---|---|---|
| Alertness/drowsiness | 42.5 ± 1.97 | 12.5 ± 1.97 | 25.6 ± 1.97 | 22.9 ± 1.97 | 17.7 ± 1.97 |
| Agitation/relaxation | 44.1 ± 1.94 | 13.4 ± 1.94 | 24.6 ± 1.94 | 22.4 ± 1.94 | 15.4 ± 1.94 |
Participants marked a point on a 100-mm horizontal line that best represented their response to the given question. The endpoints of each electronic scale were marked with descriptive anchors on a scale from 0 to 100 (Fraser et al. 1961; Bond and Lader 1974; Bigelow 1991; Shram et al. 2010). In the "How similar" questions, ranges from 0 to 100 and a score of 0 indicates definitely not similar, and a score of 100 indicates definitely similar.
| score on a scale | Placebo - Qualification Phase | 1 mg Alprazolam - Qualification Phase | Placebo | 2 mg Alprazolam | Lasmiditan - 100 mg | Lasmiditan - 200 mg | Lasmiditan - 400 mg |
|---|---|---|---|---|---|---|---|
| How similar with cocaine / | 1.3 ± 3.5 | 5.8 ± 10.6 | 2.2 ± 6.6 | 6.1 ± 13.6 | 2.7 ± 4.2 | 14.6 ± 26.3 | 12.5 ± 23.3 |
| How similar with caffeine | 2.9 ± 10.3 | 3.2 ± 6.0 | 1.5 ± 7.2 | 4.4 ± 9.7 | 2.2 ± 2.4 | 4.4 ± 9.8 | 4.1 ± 8.3 |
| How similar to MDMA (Ectasy) | 4.7 ± 13.5 | 10.0 ± 20.4 | 1.4 ± 3.9 | 20.5 ± 23.7 | 10.6 ± 19.9 | 17.1 ± 28.2 | 18.7 ± 28.2 |
| How similar to amphetamine or methamphetamine | 1.5 ± 5.4 | 4.3 ± 6.3 | 2.4 ± 6.0 | 3.9 ± 5.5 | 2.3 ± 2.5 | 4.6 ± 4.8 | 4.4 ± 6.2 |
| How similar to phencyclidine (PCP) | 22.0 ± 30.6 | 0.5 ± 1.0 | 0.0 ± 0.0 | 26.7 ± 40.3 | 1.3 ± 1.5 | 24.0 ± 37.3 | 32.3 ± 43.7 |
| How similar to codeine or morphine use | 11.4 ± 23.8 | 41.5 ± 35.1 | 8.1 ± 21.7 | 50.8 ± 31.2 | 30.9 ± 30.4 | 37.6 ± 31.7 | 45.9 ± 32.4 |
| How similar to (lysergic acid diethylamide (LSD) | 1.2 ± 3.9 | 4.1 ± 6.9 | 4.2 ± 6.6 | 6.2 ± 7.5 | 3.5 ± 4.6 | 5.9 ± 5.5 | 7.2 ± 8.0 |
| How similar to nicotine | 2.9 ± 11.8 | 5.1 ± 9.6 | 1.4 ± 5.5 | 3.8 ± 9.4 | 3.3 ± 11.0 | 3.6 ± 9.0 | 4.3 ± 8.6 |
| How similar to cannabis | 10.8 ± 24.7 | 39.9 ± 33.5 | 8.9 ± 22.9 | 51.2 ± 30.3 | 29.9 ± 30.0 | 37.4 ± 29.6 | 41.7 ± 31.6 |
| How similar to benzodiazepine | 14.4 ± 32.4 | 75.9 ± 36.2 | 13.1 ± 30.6 | 88.1 ± 22.6 | 57.2 ± 40.3 | 66.9 ± 38.7 | 74.6 ± 31.9 |
| How similar to mushrooms | 0.0 ± 0.0 | 2.7 ± 3.8 | 2.1 ± 5.2 | 3.7 ± 6.1 | 2.1 ± 2.1 | 3.8 ± 5.7 | 4.9 ± 6.3 |
| How similar to heroin | 0.0 ± 0.0 | 17.8 ± 38.1 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
Collected over From Baseline to Study Completion (Up to 2 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Qualification Phase - Placebo | 0/95 (0%) | 0/95 (0%) | 8/95 (8.4%) |
| Qualification Phase - Alprazolam | 0/94 (0%) | 0/94 (0%) | 74/94 (78.7%) |
| Treatment Phase - Placebo | 0/55 (0%) | 0/55 (0%) | 12/55 (21.8%) |
| Treatment Phase - 2 mg Alprazolam | 0/53 (0%) | 0/53 (0%) | 49/53 (92.5%) |
| Treatment Phase - 100 mg Lasmiditan | 0/55 (0%) | 0/55 (0%) | 33/55 (60%) |
| Treatment Phase - 200 mg Lasmiditan | 0/55 (0%) | 0/55 (0%) | 42/55 (76.4%) |
| Treatment Phase - 400 mg Lasmiditan | 0/55 (0%) | 0/55 (0%) | 47/55 (85.5%) |
| Event | Qualification Phase - Placebo | Qualification Phase - Alprazolam | Treatment Phase - Placebo | Treatment Phase - 2 mg Alprazolam | Treatment Phase - 100 mg Lasmiditan | Treatment Phase - 200 mg Lasmiditan | Treatment Phase - 400 mg Lasmiditan |
|---|---|---|---|---|---|---|---|
| SomnolenceNervous system disorders | 3/95 | 52/94 | 2/55 | 45/53 | 18/55 | 22/55 | 30/55 |
| Euphoric moodPsychiatric disorders | 1/95 | 22/94 | 6/55 | 23/53 | 14/55 | 27/55 | 25/55 |
| Feeling of relaxationGeneral disorders | 3/95 | 20/94 | 1/55 | 12/53 | 6/55 | 4/55 | 4/55 |
| AmnesiaNervous system disorders | 0/95 | 0/94 | 0/55 | 10/53 | 0/55 | 1/55 | 0/55 |
| DizzinessNervous system disorders | 0/95 | 1/94 | 0/55 | 2/53 | 3/55 | 6/55 | 2/55 |
| ParaesthesiaNervous system disorders | 1/95 | 0/94 | 0/55 | 1/53 | 4/55 | 6/55 | 5/55 |
| AgitationPsychiatric disorders | 0/95 | 0/94 | 0/55 | 5/53 | 1/55 | 3/55 | 2/55 |
| HeadacheNervous system disorders | 0/95 | 2/94 | 4/55 | 4/53 | 3/55 | 3/55 | 4/55 |
| Upper respiratory tract infectionInfections and infestations | 1/95 | 0/94 | 1/55 | 0/53 | 3/55 | 0/55 | 1/55 |
All randomized participants.
| Age, Continuous(years) | Overall Participants |
|---|---|
| Mean | 31.4 ± 8.6 |
| Sex: Female, Male(Participants) | Overall Participants |
|---|---|
| Female | 19 |
| Male | 77 |
| Ethnicity (NIH/OMB)(Participants) | Overall Participants |
|---|---|
| Hispanic or Latino | 5 |
| Not Hispanic or Latino | 91 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Overall Participants |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 1 |
| Black or African American | 69 |
| White | 24 |
| More than one race | 1 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Overall Participants |
|---|---|
| United States | 96 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2017 to primary completion in Nov 2017, 2 months.
Results were first posted in Jan 2020, 2 years 1 month after primary completion.
Of 24 industry-sponsored phase 1 interventional studies under Substance-Related Disorders, half reached primary completion within 4 months of starting (the median); a quarter within 3 and three quarters within 9. This study's 2 months is below that.
Counting every sponsor, half of 54 studies reached it within 12 months; a quarter within 4 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lasmiditan